STOCK TITAN

[Form 3] Evogene Ltd. Initial Statement of Beneficial Ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Evogene Ltd. filed an initial ownership report for Chief Technology Officer Ilia Zhidkov, detailing his stock option holdings in the company. The filing lists multiple options to buy ordinary shares with exercise prices ranging from 2.3050 to 49.4700 and expiration dates between 2027 and 2034. Footnotes state that certain grants from March 8, 2023 and November 20, 2024 vest 6.25% each quarter over four years until fully vested on their fourth anniversaries.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Zhidkov Ilia

(Last)(First)(Middle)
19 EGOZ ST.

(Street)
ASHDOD7777110

(City)(State)(Zip)

ISRAEL

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]
3a. Foreign Trading Symbol
[EVGN]
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technology Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy ordinary shares)08/08/202108/08/2027Ordinary shares3,000$49.47D
Stock Option (right to buy ordinary shares)07/30/202307/30/2029Ordinary shares750$15.6D
Stock Option (right to buy ordinary shares)09/01/202509/01/2031Ordinary shares8,000$28.63D
Stock Option (right to buy ordinary shares) (1)03/08/2033Ordinary shares6,000$7.745D
Stock Option (right to buy ordinary shares) (2)11/20/2034Ordinary shares40,000$2.305D
Explanation of Responses:
1. The options reported in this row were granted to the Reporting Person on March 8, 2023 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date.
2. The options reported in this row were granted to the Reporting Person on November 20, 2024 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date.
Remarks:
Exhibit 24.1 - Power of Attorney.
/s/ Nitsan Deutsch, attorney-in-fact03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)
Evogene

NASDAQ:EVGN

View EVGN Stock Overview

EVGN Rankings

EVGN Latest News

EVGN Latest SEC Filings

EVGN Stock Data

7.38M
8.63M
Biotechnology
Healthcare
Link
Israel
Rehovot